English, Article edition: The Costs and Benefits of Community Thrombolysis for Acute Myocardial Infarction: A Decision-Analytic Model Luke Vale; Harvey Steffens; Cam Donaldson

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/93823
Physical Description
  • article
Language
  • English

Edition details

Title
  • The Costs and Benefits of Community Thrombolysis for Acute Myocardial Infarction: A Decision-Analytic Model
Author
  • Luke Vale
  • Harvey Steffens
  • Cam Donaldson
Physical Description
  • article
Notes
  • Background: There is evidence that the earlier a patient reaches hospital and receives thrombolysis, the better the outcome. The GREAT (Grampian Region Early Anistreplase Trial) directly addressed the issue of early thrombolysis by evaluating, in a randomised controlled trial, the efficacy of thrombolysis in the community compared with that administered in hospital. Objective: This paper aimed to model the cost and benefits of community compared with hospital thrombolysis from the UK NHS perspective, using efficacy data from the GREAT. Methods: A decision-analytic approach was used to model these two alternatives. Resource use and cost estimates were estimated for a single tertiary centre. Estimates of effectiveness in life-years were obtained from the 4-year follow-up for patients recruited to the GREAT, using declining exponential approximation of life expectancy. Costs are in Lstg , 2000/​1 values. Results: Community thrombolysis had an average life expectancy of 12.48 years and hospital thrombolysis had an average life expectancy of 12.39 years. Costs were Lstg 361 for community thrombolysis and Lstg 300 for hospital thrombolysis. Community thrombolysis led to an additional 0.09 years of life-expectancy gained compared with hospital thrombolysis at an additional cost of Lstg 61 per patient. Therefore, the incremental cost per life-year gained for the community thrombolysis service over the hospital thrombolysis service was Lstg 667. Sensitivity analysis showed that estimates of cost per life-year gained were most sensitive to the estimates of survival. Conclusion: This model suggests that, from the UK NHS perspective, implementing community thrombolysis may lead to extra survival but at extra cost over hospital thrombolysis. Although the incremental cost per life-year is modest, judgements still have to be made, however, as to whether the extra benefits estimated are worth the additional resources required. This requires consideration of the local context in which the service may be introduced.
  • Anistreplase, Cost-effectiveness, Heparin, Myocardial-infarction, Streptokinase, Thrombolytics
  • RePEc:wkh:phecon:v:22:y:2004:i:14:p:943-954
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment